Bupivacaine - Liquidia Technologies
Alternative Names: LIQ-865; LIQ865A; LIQ865A bupivacaine formulation; LIQ865B; LIQ865B bupivacaine formulationLatest Information Update: 19 Dec 2021
At a glance
- Originator Liquidia Technologies
- Class Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Postoperative pain
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Postoperative-pain(In volunteers) in USA (SC, Injection)
- 28 Jan 2020 No recent reports of development identified for phase-I development in Postoperative-pain(In volunteers) in Denmark (SC, Injection)
- 27 May 2019 Liquidia Technologies plans initial phase II proof of concept clinical trial in 2020